[ad_1]
Samjin Pharm presents "Newstatin ™ Thesis", a combination drug for hypertension and hyperlipidemia
[현대건강신문=여혜숙 기자] Samjin Pharm Co., Ltd., a renowned company in the field of Nephrotoxin, has developed Neustatin ™, a combination therapy for hypertension and hyperlipidemia.& # 39; New statin thesis & # 39; is a combination of the telmisartan component of the angiotensin II receptor blocker (ARB), amlodipine calcium channel blocker series (ACB) and the statin (lipid-lowering agent) The statin, a combination rosuvastatin, is the product of a single schedule.
Hypertension and hyperlipidemia are risk factors for cardiovascular disease According to the Hypertension Factsheet of the Korean Society of Hypertension, hypertension and hyperlipidemia are badociated with hypertension and hyperlipidemia. Of all hypertensive patients in 2002 increased from 9.1% to 31.9% in 2016. The importance of managing these two diseases is steadily increasing. Samjin Pharm's New Statin Thesis & # 39; is a product that can immediately take the necessary ingredients for patients with essential hypertension and hyperlipidemia in order to improve the convenience of taking.
In addition to preparing for the launch of Statin TES, the company responds to personalized responses based on the patient's condition and indications, including the existing "Dustin" hypertensive / hyperlipidemic agent. , the combination of two hypertensive drugs "Aabi X- The company plans to build a range of possible treatments for cardiovascular disease and market.
Seung-Woo Lee, CEO of Sangjin Pharmaceutical Co., Ltd., said, "The new dissertation on statins, which is a combination of three drugs, can improve convenience for patients with hypertension. and hyperlipidemia. New "statin t-shirts" will be launched to address the different treatment options for medical staff and patients.
Chong Kun Dang launches the drug improving esophagitis reflux * Esdo Duo & # 39;
The first combination S omeprazole / sodium bicarbonate in the world … "src =" http://hnews.kr/data/tmp/1807/351b037b7f764e0d5be8eae70d6b29e3_mTtJRHjhwgGvWepyzM9bVBIg8R.gif "/>
